Library

A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.

1 December 2014. doid: 10.1007/s40261-014-0247-5

Wisman LA, De Cock EP, Reijers JA, Kamerling IM, Van Os SH, de Kam ML, Burggraaf J, Voortman G

View publication

Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer. FTMB is being developed as a biosimilar of trastuzumab.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact